用于肾细胞癌的抗程序性死亡受体配体1（anti-PD-L1）和酪氨酸激酶抑制剂治疗引发的致命性自身免疫性心肌炎 - Suppr

Suppr

超能文献

Fatal autoimmune myocarditis with anti-PD-L1 and tyrosine kinase inhibitor therapy for renal cell cancer.

作者信息

Berner A M, Sharma A, Agarwal S, Al-Sam S, Nathan P

机构信息

Department of Oncology, Mount Vernon Cancer Centre, Northwood HA6 2RN, UK.

出版信息

Eur J Cancer. 2018 Sep;101:287-290. doi: 10.1016/j.ejca.2018.06.021. Epub 2018 Jul 13.

DOI:10.1016/j.ejca.2018.06.021

PMID:30017380

Abstract

摘要

相似文献

Fatal autoimmune myocarditis with anti-PD-L1 and tyrosine kinase inhibitor therapy for renal cell cancer.

Eur J Cancer. 2018 Sep;101:287-290. doi: 10.1016/j.ejca.2018.06.021. Epub 2018 Jul 13.

Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.

Lancet Oncol. 2018 Apr;19(4):451-460. doi: 10.1016/S1470-2045(18)30107-4. Epub 2018 Mar 9.

Avelumab and axitinib combination therapy for the treatment of advanced renal cell carcinoma.

Future Oncol. 2020 Dec;16(36):3021-3034. doi: 10.2217/fon-2020-0586. Epub 2020 Aug 28.

Axitinib-ICIs boost the RCC armamentarium.

Nat Rev Clin Oncol. 2019 Apr;16(4):207. doi: 10.1038/s41571-019-0193-5.

Axitinib Reverses Resistance to Anti-Programmed Cell Death-1 Therapy in a Patient With Renal Cell Carcinoma.

Front Immunol. 2021 Oct 26;12:728750. doi: 10.3389/fimmu.2021.728750. eCollection 2021.

Cutaneous collagenous vasculopathy induced by the vascular endothelial growth factor receptor inhibitor axitinib.

Int J Dermatol. 2018 Dec;57(12):e167-e169. doi: 10.1111/ijd.14243. Epub 2018 Sep 19.

Check point inhibitors a new era in renal cell carcinoma treatment.

Med Oncol. 2018 May 4;35(6):85. doi: 10.1007/s12032-018-1147-y.

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma.

Nat Commun. 2016 Aug 30;7:12624. doi: 10.1038/ncomms12624.

Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.

Curr Treat Options Oncol. 2017 Jan;18(1):7. doi: 10.1007/s11864-017-0458-0.

Tyrosine kinase inhibitors in renal cell cancer: Losing an empire and yet to find a role.

Eur J Cancer. 2015 Nov;51(17):2578-9. doi: 10.1016/j.ejca.2015.10.001.

引用本文的文献

Immunotherapy-Induced Cardiotoxicity: A Narrative Review of Real-World Case Reports, Recent Information and Clinical Evidence.

Cardiovasc Toxicol. 2025 Jul 13. doi: 10.1007/s12012-025-10038-y.

Immune checkpoint inhibitors break whose heart? Perspectives from cardio-immuno-oncology.

Genes Dis. 2023 Mar 24;11(2):807-818. doi: 10.1016/j.gendis.2023.01.024. eCollection 2024 Mar.

Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis.

Cell Rep. 2022 Nov 8;41(6):111611. doi: 10.1016/j.celrep.2022.111611.

Cardiac Remodelling Following Cancer Therapy: A Review.

Cardiovasc Toxicol. 2022 Sep;22(9):771-786. doi: 10.1007/s12012-022-09762-6. Epub 2022 Jul 25.

PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines.

J Adv Res. 2020 Oct 3;29:45-54. doi: 10.1016/j.jare.2020.09.006. eCollection 2021 Mar.

Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management.

Front Pharmacol. 2019 Nov 29;10:1350. doi: 10.3389/fphar.2019.01350. eCollection 2019.

Immunotherapy in Urological Tumors.

Rev Urol. 2019;21(1):15-20.

Heart failure in cancer: role of checkpoint inhibitors.

J Thorac Dis. 2018 Dec;10(Suppl 35):S4323-S4334. doi: 10.21037/jtd.2018.10.07.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验